EU Approves Trastuzumab Biosimilar for HER2+ Breast, Gastric Cancers

August 1, 2018 – PF-05280014, a biosimilar for trastuzumab, has been approved for use in the European Union (EU) to treat patients with HER2 overexpressing metastatic or early breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The EU’s Committee for Medicinal Products for Human Use issued a positive opinion on PF-05280014 in May. Pfizer, the manufacturer of PF-05280014, issued a release announcing the … (leggi tutto)